Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of cancer on diabetes outcomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course

    Research output: Contribution to journalJournal articleResearchpeer-review

  • David J Stott
  • Jacobijn Gussekloo
  • Patricia M Kearney
  • Nicolas Rodondi
  • Rudi G J Westendorp
  • Simon Mooijaart
  • Sharon Kean
  • Terence J Quinn
  • Naveed Sattar
  • Kirsty Hendry
  • Robert Du Puy
  • Wendy P J Den Elzen
  • Rosalinde K E Poortvliet
  • Jan W A Smit
  • J Wouter Jukema
  • Olaf M Dekkers
  • Manuel Blum
  • Tinh-Hai Collet
  • Vera McCarthy
  • Caroline Hurley
  • Stephen Byrne
  • John Browne
  • Torquil Watt
  • Douglas Bauer
  • Ian Ford
View graph of relations

BACKGROUND: Subclinical hypothyroidism (SCH) is a common condition in elderly people, defined as elevated serum thyroid-stimulating hormone (TSH) with normal circulating free thyroxine (fT4). Evidence is lacking about the effect of thyroid hormone treatment. We describe the protocol of a large randomised controlled trial (RCT) of Levothyroxine treatment for SCH.

METHODS: Participants are community-dwelling subjects aged ≥65 years with SCH, diagnosed by elevated TSH levels (≥4.6 and ≤19.9 mU/L) on a minimum of two measures ≥ three months apart, with fT4 levels within laboratory reference range. The study is a randomised double-blind placebo-controlled parallel group trial, starting with levothyroxine 50 micrograms daily (25 micrograms in subjects <50Kg body weight or known coronary heart disease) with titration of dose in the active treatment group according to TSH level, and a mock titration in the placebo group. The primary outcomes are changes in two domains (hypothyroid symptoms and fatigue / vitality) on the thyroid-related quality of life questionnaire (ThyPRO) at one year. The study has 80% power (at p = 0.025, 2-tailed) to detect a change with levothyroxine treatment of 3.0% on the hypothyroid scale and 4.1% on the fatigue / vitality scale with a total target sample size of 750 patients. Secondary outcomes include general health-related quality of life (EuroQol), fatal and non-fatal cardiovascular events, handgrip strength, executive cognitive function (Letter Digit Coding Test), basic and instrumental activities of daily living, haemoglobin, blood pressure, weight, body mass index and waist circumference. Patients are monitored for specific adverse events of interest including incident atrial fibrillation, heart failure and bone fracture.

DISCUSSION: This large multicentre RCT of levothyroxine treatment of subclinical hypothyroidism is powered to detect clinically relevant change in symptoms / quality of life and is likely to be highly influential in guiding treatment of this common condition.

TRIAL REGISTRATION: NCT01660126 ; registered 8th June 2012.

Original languageEnglish
JournalBMC Endocrine Disorders
Issue number1
Pages (from-to)e6
Publication statusPublished - 3 Feb 2017

    Research areas

  • Aged, Blood Banks, Clinical Protocols, Double-Blind Method, Hormone Replacement Therapy, Humans, Hypothyroidism, Patient Safety, Thyroxine, Journal Article, Randomized Controlled Trial

ID: 52568568